Working… Menu

Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (VIP Extend)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03795428
Recruitment Status : Recruiting
First Posted : January 7, 2019
Last Update Posted : September 8, 2021
Information provided by (Responsible Party):
PhaseBio Pharmaceuticals Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 15, 2024
Estimated Study Completion Date : February 15, 2024